Mantle Cell Lymphoma (MCL) Active Not Recruiting Phase 2 Trials for Rituximab (DB00073)

Also known as: Lymphoma, Mantle-Cell / Mantle Cell Lymphoma / Mantle-Cell Lymphoma / Lymphoma, Mantle- Cell / Lymphoma, Mantle Cell / Mantle-Cell Lymphomas / B cell lymphoma / Centrocytic lymphoma / Mantle cell lymphoma NOS / Mantle cell lymphomas

IndicationStatusPhase
DBCOND0071979 (Mantle Cell Lymphoma (MCL))Active Not Recruiting2
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT00875667A Study to Determine the Efficacy of Lenalidomide Versus Investigator's Choice in Patients With Relapsed or Refractory Mantle Cell Lymphoma (MCL)Treatment
NCT00878254Rituximab and Combination Chemotherapy in Treating Patients With Previously Untreated Mantle Cell LymphomaTreatment
NCT02267915Phase II of Efficacy and Toxicity of Maintenance Sub. Rituximab After Induction in Relapsed MCL and Non-eligible HSCTTreatment
NCT00783367Combination Therapy Using Lenalidomide (Revlimid)- Low Dose Dexamethasone and Rituximab for Treatment of Rituximab-Resistant, Non-Aggressive B-Cell LymphomasTreatment
NCT00114738EPOCH-R Chemotherapy Plus Bortezomib to Treat Mantle Cell LymphomaTreatment
NCT01661881Rituximab/Bendamustine + Rituximab/Cytarabine for Mantle Cell LymphomaTreatment
NCT02427620Ibrutinib, Rituximab, and Consolidation Chemotherapy in Treating Young Patients With Newly Diagnosed Mantle Cell LymphomaTreatment
NCT01472562Lenalidomide Plus Rituxan for Untreated Mantle Cell LymphomaTreatment
NCT01665768Maintenance Rituximab With mTor Inhibition After High-dose Consolidative Therapy in LymphomaTreatment
NCT00992446Bortezomib and Vorinostat as Maintenance Therapy After Autologous Stem Cell Transplant in Treating Patients With Non-Hodgkin LymphomaTreatment